Compare EHI & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHI | STXS |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 164.1M |
| IPO Year | 2003 | 2004 |
| Metric | EHI | STXS |
|---|---|---|
| Price | $5.84 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 91.0K | ★ 901.4K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,346,617.00 |
| Revenue This Year | N/A | $28.22 |
| Revenue Next Year | N/A | $30.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.75 | $1.24 |
| 52 Week High | $6.70 | $3.59 |
| Indicator | EHI | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 41.60 |
| Support Level | $5.80 | N/A |
| Resistance Level | $6.03 | $1.97 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 44.39 | 50.00 |
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income. The Fund's secondary investment objective is total return. It invests in an international portfolio of securities consisting of below-investment-grade fixed income securities, emerging market fixed income securities, and investment-grade fixed income securities. The Fund's investment portfolio comprises sovereign bonds, collateralized mortgage obligations, asset-backed securities, and fixed income securities from different corporate sectors, including financials, energy, consumer discretionary, and industrials, among others.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.